The Motley Fool
04 Jul 2026, 13:21 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Recursion Pharmaceuticals achieved approximately $74.7 million in FY 2025 revenue, marking nearly 27% year-over-year growth. — Revenue growth in a clinical-stage AI biotech firm suggests successful commercial validation and scaling of its platform partnerships.
+0.40Dyne Therapeutics reported a net loss of $446.2 million for FY 2025, an increase from the $317.4 million loss the prior year. — Increasing losses indicate rising clinical trial costs and a higher cash burn rate, increasing the risk for shareholders.
-0.30Recursion Pharmaceuticals maintains strategic collaborations and technical relationships with major industry players including Roche, Genentech, Takeda, Bayer, Merck, Sanofi, and Nvidia. — High-profile partnerships provide non-dilutive capital and critical industry validation for the company's AI discovery platform.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Dyne Therapeutics relies on a single loan agreement with Hercules Capital as its only committed source of external capital. — High customer/creditor concentration increases financial vulnerability if the funding relationship is disrupted.
-0.20Which stocks this story touches
Positive stock price movement, revenue growth, and strong validation through strategic AI partnerships.
Positive stock price movement and focused development platform, though offset by increasing net losses.
Maintaining a technical relationship with Recursion Pharmaceuticals and showing positive price movement.
Maintaining a technical relationship with Recursion Pharmaceuticals and showing positive price movement.
Identified as a strategic collaborator for Recursion Pharmaceuticals with positive stock price movement.
Mentioned as a capital provider for Dyne Therapeutics with a slight positive price movement.
Listed as a technical partner for Recursion's AI platform with slight positive price movement.
[a_to_b] Hercules Capital provides Dyne Therapeutics with its only committed source of external capital via a loan agreement.
[mutual] Recursion Pharmaceuticals generates revenue through strategic collaborations with partners including Takeda Pharmaceutical.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1h ago
[mutual] Recursion Pharmaceuticals maintains a technical relationship with Merck & Co.
[mutual] Recursion Pharmaceuticals maintains a technical relationship with Sanofi SA.
[mutual] Recursion Pharmaceuticals maintains a technical relationship with Nvidia.
